[at Motley Fool] – Gilead Sciencs releases data that appears to show its drugs work better than AbbVie’s drug combo, although both drugs work better than first-generation drugs from Vertex Pharmaceuticals and Merck.
Read more on this.
AbbVie Inc. … [visit site to read more]
Similar posts:- Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1
- AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial
- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review
